BioCentury
ARTICLE | Finance

Sequenom Chronicles

May 4, 2009 7:00 AM UTC

Sequenom Inc. (NASDAQ:SQNM) fell 71% on the week after reporting after market close Wednesday that it delayed the expected June launch of its SEQureDx Trisomy 21 test for Down syndrome due to "employee mishandling" of data. The stock was up 108% in 2008 on announcements of positive data on the test. Selected events tracked against Sequenom's weekly stock price since the start of 2004, when the company began to focus on its genetic analysis business...